AKT1 and neoplasm: No complete response was observed, but 46% of the patients showed stable disease with concurrent reduction in MAPK and PI3K/AKT signaling cascade activation, and an increase in infiltration of lymphocytes within the stromal/tumor junctions only in post-treatment stable disease patient samples [67].